Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02592551 · ClinicalTrials.gov registry record · Phase 2
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
A Phase 2 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02592551 is a Phase 2 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 24 participants.
The verdict
NCT02592551, a Phase 2 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to determine whether MEDI4736 or combination therapy with MEDI4736 + tremelimumab are associated with favorable alterations of the intratumoral immunologic environment in subjects undergoing resectional surgery for Malignant Pleural Mesothelioma MPM.
Interventions
- DRUG Tremelimumab
- DRUG MEDI4736
- OTHER no other name
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02592551
The ClinicalTrials.gov registry entry for NCT02592551 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tremelimumab is the first listed.
NCT02592551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02592551 about?
NCT02592551 is a clinical study titled "MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma". The objective of this study is to determine whether MEDI4736 or combination therapy with MEDI4736 + tremelimumab are associated with favorable alterations of the intratumoral immunologic environment in subjects undergoing resectional surgery for Malignant Pleural Mesothelioma MPM.
What is the current status of trial NCT02592551?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-05-11. Estimated completion is 2022-09-01.
What interventions are being tested in trial NCT02592551?
The interventions under investigation include: Tremelimumab (DRUG), MEDI4736 (DRUG), no other name (OTHER).
Who is sponsoring clinical trial NCT02592551?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.